Bridge Therapeutics
Bridge Therapeutics, Inc. is a development-stage pharmaceutical company based in Mountain Brook, AL, dedicated to improving the healthcare of millions of patients. They are focused on pursuing FDA approval for BT 219, a superior delivery of buprenorphine-naloxone for opioid use disorder (OUD), and BT-205, a patented drug combination for the treatment of chronic pain in opioid-experienced patients.
With a mission to provide safer and more effective therapies, Bridge Therapeutics aims to separate pain from addiction, offering OUD patients a superior form of buprenorphine-naloxone and enabling chronic pain patients to transition from standard opioid therapy to BT-205 without withdrawal and without experiencing euphoria, which is a common reason for painkiller abuse.
Generated from the website





